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Prescription opioid use in the United States has become 
widespread (1), and studies of opioid exposure in pregnancy 
suggest increased risk for adverse pregnancy outcomes, includ-
ing neonatal abstinence syndrome and birth defects (e.g., 
neural tube defects, gastroschisis, and congenital heart defects) 
(2,3). The development of birth defects often results from 
exposures during the first few weeks of pregnancy, which is a 
critical period for organ formation. Given that many pregnan-
cies are not recognized until well after the first few weeks and 
half of all U.S. pregnancies are unplanned (4), all women who 
might become pregnant are at risk. Therefore, it is important 
to assess opioid medication use among all women of reproduc-
tive age. CDC used Truven Health’s MarketScan Commercial 
Claims and Encounters and Medicaid data* to estimate the 
number of opioid prescriptions dispensed by outpatient 
pharmacies to women aged 15–44 years. During 2008–2012, 
opioid prescription claims were consistently higher among 
Medicaid-enrolled women when compared with privately 
insured women (39.4% compared with 27.7%, p<0.001). 
The most frequently prescribed opioids among women in 
both groups were hydrocodone, codeine, and oxycodone. 
Efforts are needed to promote interventions to reduce opioid 
prescriptions among this population when safer alternative 
treatments are available.
CDC used Truven Health’s MarketScan Commercial Claims 
and Encounters and Medicaid data from 2008–2012 to assess 
outpatient pharmacy prescription drug claims for opioid-
containing medications among reproductive-aged women 
(15–44 years). The Commercial Claims and Encounters data 
represent a convenience sample of employed persons with 
private employer–sponsored insurance and their dependents. 
The Medicaid data are an annual sample of Medicaid recipients 
in 10–13 states across the United States. Both data sources 
include person-level information (e.g., age, sex, and enroll-
ment period) and claim-level data (e.g., outpatient pharmacy 
prescription claims). This analysis was restricted to women 
continuously enrolled (≥365 days) for the year under study in 
a private insurance or Medicaid plan that included prescription 
drug coverage. Outpatient pharmacy prescription medication 
claims were searched for opioid-containing medications using 
national drug codes; pure opioid antagonists (e.g., naloxone), 
medications that block the effects of opioids, were excluded 
when not combined with an opioid (e.g., buprenorphine/
naloxone). For each woman, the prescription claims data were 
analyzed to determine whether she had ever filled a prescription 
for an opioid medication from an outpatient pharmacy during 
a given calendar year. The annual proportion of reproductive-
aged women with outpatient prescription claims for an opioid 
during 2008–2012 was examined by health care coverage type 
and specific opioid medication, age group, U.S. geographic 
region (only available for privately insured women), and race/
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ethnicity (only available for Medicaid-enrolled women). The 
average proportion of reproductive-aged women who filled 
a prescription for an opioid from an outpatient pharmacy 
each year was also estimated. Chi-square tests were used to 
determine whether significant differences existed between 
the frequency of opioid claims among privately insured and 
Medicaid-enrolled women. 
There were approximately 4.4–6.6 million privately insured 
and 0.4–0.8 million Medicaid-enrolled reproductive-aged 
women in the study sample each year during 2008–2012. Of 
these, on average 27.7% of privately insured and 39.4% of 
Medicaid-enrolled women filled a prescription for an opioid 
from an outpatient pharmacy each year (p<0.001). Opioid 
prescription claims were highest in 2009 with 29.1% of 
privately insured women and 41.4% of Medicaid-enrolled 
women filling a prescription for an opioid. During 2008–2012, 
opioid prescription claims were consistently higher among 
Medicaid-enrolled women when compared with privately 
insured women (Figure 1). In 2012, there were 0.7 and 1.6 
prescriptions filled per woman among privately insured and 
Medicaid-enrolled women, respectively; of those who filled an 
opioid prescription, an average of 2.6 and 4.3 prescriptions 
were filled, respectively (Figure 2). 
The most commonly prescribed opioids during 2008–2012 
were hydrocodone (reported by an average of 17.5% of pri-
vately insured and 25.0% of Medicaid-enrolled women each 
year), codeine (6.9% and 9.4%), and oxycodone (5.5% and 
13.0%) (Table). Privately insured women aged 30–34 years and 
Medicaid-enrolled women aged 40–44 years were most likely 
to fill prescriptions for opioids (Table). Among women with 
either type of health care coverage, women aged 15–19 years 
were least likely to fill a prescription for an opioid. Overall, for 
all age groups, women with Medicaid filled prescriptions for 
opioids more frequently than women with private insurance. 
Significant regional and racial/ethnic differences were 
observed. Among privately insured women, opioid prescrip-
tion claims were highest among those residing in the South. 
Among Medicaid-enrolled women, opioid prescription claims 
were highest among non-Hispanic whites (p<0.001) (Table).
Discussion
Opioid-containing medications are widely prescribed among 
reproductive-aged women with either private insurance or 
Medicaid, with approximately one fourth of privately insured 
and over one third of Medicaid-enrolled women filling a 
prescription for an opioid each year during 2008–2012. In 
addition, CDC found an average of three opioids prescribed 
for every four privately insured women and nearly two opioid 
prescriptions for every one Medicaid-enrolled woman per year. 
This is a significant public health concern given evidence of 
adverse pregnancy outcomes with opioid exposure, the likeli-
hood of exposures occurring among unrecognized or unin-
tended pregnancies, and health care provider concerns about 
using other pain medications during early pregnancy (2,4,5). 
This analysis presents data among all reproductive-aged 
women; however, previous studies from slightly earlier time 
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periods have reported data among women who were actually 
pregnant. In general, more reproductive-aged women filled a 
prescription for an opioid in this study compared with what 
has been found among pregnant women. In a study of approxi-
mately 534,000 pregnant women with private insurance 
during 2005–2011, 14.4% filled a prescription for an opioid 
during pregnancy (6). In a study of approximately 1.1 million 
Medicaid-enrolled women nationwide with pregnancies during 
2000–2007, 21.6% filled a prescription for an opioid from 
an outpatient pharmacy during pregnancy (7), and opioid 
dispensing increased over time. Similar to the findings in this 
report, these two previous studies of pregnant women also 
reported hydrocodone, codeine, and oxycodone as among the 
opioids most commonly dispensed by outpatient pharmacies. 
The consistently higher frequency of opioid prescribing to 
Medicaid-enrolled women is of concern because approximately 
50% of U.S. births occur to Medicaid-enrolled women (8). 
Other studies have found higher opioid prescribing rates to 
Medicaid-enrolled populations as compared with privately 
insured populations, but these have not specifically assessed 
use in reproductive-aged women. One study showed that, in 
2005, 17% of a sample of persons aged ≥18 years enrolled in 
a multistate private insurance plan received an opioid pre-
scription, compared with 30% of those enrolled in Arkansas 
Medicaid (9). These differences by health care coverage type 
might reflect differences in health plan drug formularies, dif-
ferences in patient use of health care services based on health 
care coverage, or differences in the prevalence of underlying 
health conditions among Medicaid recipients compared with 
persons covered by employer-provided private health insurance.
Geographic region was available for the privately insured 
claims data and showed opioid prescription rates were high-
est among reproductive-aged women residing in the South 
and lowest in the Northeast. Race/ethnicity was available for 
Medicaid data, and indicated opioid prescriptions were nearly 
1.5 times higher among non-Hispanic white reproductive-aged 
FIGURE 1. Percentage of women aged 15–44 years who filled a 
prescription for an opioid from an outpatient pharmacy, by health 


































Source: Truven Health’s MarketScan Commercial Claims and Encounters and 
Medicaid data.
FIGURE 2. Average number of opioid prescriptions filled at an 
outpatient pharmacy per woman aged 15–44 years, among women 
with private insurance and Medicaid — United States, 2008–2012
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Source: Truven Health’s MarketScan Commercial Claims and Encounters and 
Medicaid data.
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women than among non-Hispanic black or Hispanic women. 
Other reports of opioid prescribing patterns have shown similar 
geographic trends, with the South having the greatest number 
of prescription opioid claims (1,6,7), and white women being 
more likely than women of other racial/ethnic populations to 
fill an opioid prescription (7). 
Although there appeared to be a decline in the frequency 
of opioids prescribed to both privately insured and Medicaid-
enrolled women of reproductive age from 2009 to 2012, any 
conclusions about changes over time must be interpreted with 
caution. The apparent decline might indicate improvements 
in opioid prescribing practices; however, given the potential 
changes in the composition of the sample used for the privately 
insured claims data and in the states included in the Medicaid 
sample each year, this conclusion cannot be drawn from 
these data. At least one study has noted a decrease in opioid 
prescriptions among pregnant women, with a decline from 
14.9% in 2005 to 12.9% in 2011 (6), although studies focused 
on earlier time periods have not noted such a decline (7,9). 
Notably, recently implemented federal regulation of certain 
opioid medications, such as hydrocodone, might decrease use 
in these populations (10).
The findings in this report are subject to at least four limita-
tions. First, Truven Health’s MarketScan Commercial Claims 
and Encounters and Medicaid data are samples and might 
not be generalizable to the entire U.S. population. Although 
TABLE. Percentage of women aged 15–44 years who filled a prescription for an opioid from an outpatient pharmacy, by health care coverage 
type and year — United States, 2008–2012
Characteristic
Privately insured Medicaid-enrolled
2008 2009 2010 2011 2012
Average 
2008–




Total women† 4,440,181 5,225,282 5,635,375 6,417,512 6,598,518 422,602 552,425 568,802 534,976 803,920
Age group (yrs) 
15–19 21.2 22.0 20.2 20.1 19.3 20.4 25.3 26.9 26.8 26.1 24.6 25.9
20–24 25.8 26.2 23.9 23.1 22.0 23.8 41.6 44.5 43.5 43.0 37.8 41.7
25–29 31.2 31.1 29.7 29.1 27.6 29.6 46.5 50.0 48.6 48.3 41.9 46.6
30–34 32.1 31.9 30.8 30.7 29.7 30.9 47.8 51.8 50.5 50.6 44.9 48.7
35–39 31.4 31.4 30.3 30.0 29.2 30.4 50.0 53.1 52.1 53.4 46.4 50.6
40–44 31.0 30.8 29.9 29.6 28.8 29.9 52.5 54.4 53.6 56.4 48.0 52.5
Geographic region§
Northeast 22.6 22.4 21.5 22.0 21.0 21.8
North central 26.6 26.6 25.2 25.1 23.9 25.4
South 32.2 32.7 31.8 30.7 30.4 31.5
West 27.8 28.5 26.8 26.4 24.6 26.6
Unknown 24.4 23.5 22.1 28.9 27.6 27.3
Race/Ethnicity¶
White, non-Hispanic 49.2 49.7 48.1 45.7 42.1 46.4
Black, non-Hispanic 35.5 38.5 38.0 35.7 31.0 35.2
Hispanic 39.3 37.7 34.9 33.4 26.0 33.6
Other race 22.0 26.5 22.3 37.1 34.6 28.0
Specific opioids**
Hydrocodone 18.0 17.8 17.3 17.6 16.9 17.5 22.9 25.1 26.4 27.0 23.9 25.0
Codeine 7.2 7.9 6.8 6.8 6.2 6.9 10.9 11.7 9.6 9.1 7.1 9.4
Oxycodone 5.2 5.4 5.6 5.7 5.5 5.5 13.2 13.4 12.7 13.4 12.5 13.0
Tramadol 2.4 2.5 2.7 3.3 3.4 2.9 6.8 7.9 8.5 9.7 8.9 8.5
Propoxyphene†† 3.9 3.3 2.7 — — 1.8 6.8 6.4 5.4 — — 3.3
Hydromorphone 0.2 0.3 0.3 0.3 0.3 0.3 0.6 0.7 1.1 1.2 0.9 0.9
Meperidine 0.5 0.3 0.2 0.2 0.2 0.3 0.6 0.4 0.3 0.3 0.2 0.3
Morphine 0.2 0.1 0.1 0.1 0.1 0.1 0.8 0.6 0.6 0.5 0.5 0.6
Buprenorphine 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.3 0.3 0.4 0.5 0.3
Fentanyl 0.1 0.1 0.1 0.1 0.1 0.1 1.0 1.1 1.6 1.7 1.2 1.3
Tapentadol 0.0 0.0 0.1 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.1
Dihydrocodeine 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1
Methadone 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.2 0.2 0.2
Source: Truven Health’s MarketScan Commercial Claims and Encounters and Medicaid data.
 * The same woman might have been included in multiple years of data. 
 † Continuously enrolled (member days ≥365) in a plan that includes prescription drug coverage.
 § Geographic region is not included in Truven Health’s Medicaid data.
 ¶ Race/ethnicity is not included in Truven Health’s Commercial Claims and Encounters data.
 ** Not mutually exclusive; among prescriptions filled by at least 0.1% of privately insured or Medicaid-enrolled women on average each year during 2008–2012.
 †† Discontinued after 2010.
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the privately insured claims data represent approximately 
4–6 million insured persons, it is likely that they are only rep-
resentative of persons with employer-based private insurance. 
The 10–13 states that contribute their data to the Medicaid 
sample each year do so anonymously. Therefore, changes over 
time in the Medicaid data might reflect changes in the sample 
of states, instead of broader changes among the Medicaid-
enrolled population. It is also likely that certain women will 
be included in multiple years of either the Commercial Claims 
and Encounters or Medicaid data. Second, pregnant women 
were not identified in this analysis; the study population was 
based on female sex and age 15–44 years alone. Whether 
opioid prescriptions were limited to infertile or contracept-
ing women was not ascertained. Third, these analyses likely 
underestimate opioid use, because the data only represent out-
patient pharmacy claims. No information on inpatient opioid 
use, opioids obtained without a prescription, or opioids paid 
for out-of-pocket was available. Finally, although these data 
represent opioids dispensed by outpatient pharmacies, there 
was no verification that women actually took the medications. 
This analysis used a large database to estimate the proportion 
of privately insured and Medicaid-enrolled reproductive-aged 
women who filled a prescription for an opioid from an outpatient 
pharmacy. Many women need to take opioid-containing medica-
tions to appropriately manage their health conditions; however, 
in some instances safer alternative treatments are available and 
use of opioids is unnecessary. Having a better understanding of 
prescription opioid use just before and during early pregnancy 
can help inform targeted interventions to reduce unnecessary 
prescribing of opioids and provide evidence-based information 
to health care providers and women about the risks of prenatal 
opioid exposure. 
 1Division of Birth Defects and Developmental Disabilities, National Center 
on Birth Defects and Developmental Disabilities, CDC (Corresponding author: 
Jennifer Lind, jlind@cdc.gov, 404-639-3286)
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What is already known on this topic? 
Opioid use among women of reproductive age is a concern 
because opioid medications have been linked to birth defects 
and other adverse pregnancy outcomes. Given the high rate 
(approximately 50%) of unintended pregnancies in the United 
States, opioid use among reproductive-aged women can result 
in many early pregnancy exposures. 
What is added by this report? 
During 2008–2012, more than one fourth of privately insured 
and more than one third of Medicaid-enrolled reproductive-
aged women (15–44 years) filled a prescription for an opioid 
from an outpatient pharmacy each year. Prescription rates were 
consistently higher among Medicaid-enrolled women when 
compared with privately insured women.
What are the implications for public health practice?
More targeted interventions and communications strategies 
are needed to reduce unnecessary prescribing and use of 
opioid-containing medications, particularly among women 
who might become pregnant.
